Loyal Valley Capital
Deal focus: Pop Mart dominates China's dolls
Best known in China for the Molly series of fashion dolls, Pop Mart emerged as a leader before many others recognized the market potential. The Loyal Valley Capital-backed company is now preparing for an IPO
Chinese toy figurine retailer Pop Mart raises $100m
Chinese black-box doll retailer Pop Mart has raised more than $100 million in funding from China Renaissance and Loyal Valley Capital in what is expected to be its last round before an IPO.
Akeso Biopharma trades up after $333m Hong Kong IPO
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO....
Temasek leads $70m Series C for China's Abbisko Therapeutics
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
China's Loyal Valley recruits ex-Blackstone executive
Brian Chi, who previously spent more than a decade making China investments for The Blackstone Group and Morgan Stanley Private Equity Asia (MSPEA), has joined Loyal Valley Capital as a partner.
PE-backed InnoCare raises $288m in Hong Kong IPO
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
Trustbridge backs Chinese storytelling start-up
Chinese children’s storytelling start-up Kaishu Story, also known as Kaishu Jianggushi, has raised $66 million in an extended tranche of Series C round led by Trustbridge Partners.
PE-backed Akeso Biopharma targets Hong Kong IPO
Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
China's Loyal Valley closes second US dollar fund at $465m
China’s Loyal Valley Capital has closed its second US dollar-denominated fund at $465 million. The target was $400 million with a hard cap of $440 million.
Chinese antibody drug developer raises $150m
Akeso Biopharma, a Chinese biotech company specializing in antibody drugs, has raised a $150 million Series D round led by Loyal Valley Capital and Sino Biopharm.
China secondaries: Curious conversions
An exit lag and difficulties raising money for renminbi funds in China has created a novel opening for secondaries investors comfortable moving assets from one currency to another
China's Allist Pharmaceuticals raises $171m Series A
Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
Deal focus: Gaosi Education stresses its B2B credentials
As China's mainstream online tuition players battle for the hearts, minds and wallets of end users, Gaosi Education found a niche targeting the B2B market. It recently raised $140 million to accelerate expansion
Warburg Pincus leads Series D for China's Gaosi Education
Gaosi Education, which provides tutoring services to schools and other educational institutions in China, has raised $140 million in Series D funding led by Warburg Pincus.
Qiming leads $42m Series B for China cancer drug developer
Qiming Venture Partners has led a $42 million Series B round for Chinese cancer drug developer Abbisko.
FOMO is the biggest risk for China investors - AVCJ Forum
The best way for private equity and venture capital investors to manage their China risk is to not deploy capital if they are only motivated by a fear of missing out (FOMO), GPs told the AVCJ China Forum.
Asia GP-led secondaries hit record high in 2018
An increase in GP-led transactions propelled Asia secondary market volume to $7.8 billion last year, and more of the same is expected in 2019 – once managers have adjusted their mark-to-market valuations following fourth-quarter volatility in the public...
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
Fosun-owned Henlius Biotech files for Hong Kong IPO
Shanghai Henlius Biotech, a Chinese drug developer controlled by Fosun Group, has filed for a Hong Kong IPO. Third-party investors include Loyal Valley Capital and China International Capital Corporation (CICC).
Junshi Biosciences seeks up to $414m in HK offering
Shanghai Junshi Biosciences, a Chinese drug developer backed by Hillhouse Capital, is seeking to raise up to HK$3.2 billion ($414 million) through a Hong Kong IPO.